American Association for Cancer Research
10780432ccr200472-sup-236987_2_supp_6408148_qd3fsw.pptx (9.77 MB)

Figure S1-S11 from Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment

Download (9.77 MB)
posted on 2023-03-31, 22:10 authored by Susannah L. Hewitt, Dyane Bailey, John Zielinski, Ameya Apte, Faith Musenge, Russell Karp, Shannon Burke, Fabien Garcon, Ankita Mishra, Sushma Gurumurthy, Amanda Watkins, Kristen Arnold, James Moynihan, Eleanor Clancy-Thompson, Kathy Mulgrew, Grace Adjei, Katharina Deschler, Darren Potz, Gordon Moody, David A. Leinster, Steve Novick, Michal Sulikowski, Chris Bagnall, Philip Martin, Jean-Martin Lapointe, Han Si, Chris Morehouse, Maja Sedic, Robert W. Wilkinson, Ronald Herbst, Joshua P. Frederick, Nadia Luheshi

Supplementary Figures S1-S11



While immune checkpoint inhibitors such as anti–PD-L1 are rapidly becoming the standard of care in the treatment of many cancers, only a subset of treated patients have long-term responses. IL12 promotes antitumor immunity in mouse models; however, systemic recombinant IL12 had significant toxicity and limited efficacy in early clinical trials. We therefore designed a novel intratumoral IL12 mRNA therapy to promote local IL12 tumor production while mitigating systemic effects. A single intratumoral dose of mouse (m)IL12 mRNA induced IFNγ and CD8+ T-cell–dependent tumor regression in multiple syngeneic mouse models, and animals with a complete response demonstrated immunity to rechallenge. Antitumor activity of mIL12 mRNA did not require NK and NKT cells. mIL12 mRNA antitumor activity correlated with TH1 tumor microenvironment (TME) transformation. In a PD-L1 blockade monotherapy-resistant model, antitumor immunity induced by mIL12 mRNA was enhanced by anti–PD-L1. mIL12 mRNA also drove regression of uninjected distal lesions, and anti–PD-L1 potentiated this response. Importantly, intratumoral delivery of mRNA encoding membrane-tethered mIL12 also drove rejection of uninjected lesions with very limited circulating IL12p70, supporting the hypothesis that local IL12 could induce a systemic antitumor immune response against distal lesions. Furthermore, in ex vivo patient tumor slice cultures, human IL12 mRNA (MEDI1191) induced dose-dependent IL12 production, downstream IFNγ expression and TH1 gene expression. These data demonstrate the potential for intratumorally delivered IL12 mRNA to promote TH1 TME transformation and robust antitumor immunity.See related commentary by Cirella et al., p. 6080

Usage metrics

    Clinical Cancer Research



    Ref. manager